Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for… EP News Bureau Apr 10, 2025 AXS-05 emerges as a potential first-in-class, non-antipsychotic treatment for Alzheimer’s agitation, positioning Axsome…
Pharma manufacturing across Southern India has strong M&A potential: GlobalData EP News Bureau Oct 2, 2020 Karnataka has one of the fastest-growing pharma sectors in India: approximately 40 per cent of the state’s pharma production is…
